- Home
- ACIU vs FLC Comparison
ACIU vs FLC Comparison
Compare ACIU & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- FLC
- Stock Information
- Founded
- ACIU 2003
- FLC 2003
- Country
- ACIU Switzerland
- FLC United States
- Employees
- ACIU N/A
- FLC N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- ACIU Health Care
- FLC Finance
- Exchange
- ACIU Nasdaq
- FLC Nasdaq
- Market Cap
- ACIU 213.3M
- FLC 174.2M
- IPO Year
- ACIU 2016
- FLC N/A
- Fundamental
- Price
- ACIU $2.04
- FLC $17.21
- Analyst Decision
- ACIU Strong Buy
- FLC
- Analyst Count
- ACIU 1
- FLC 0
- Target Price
- ACIU $12.00
- FLC N/A
- AVG Volume (30 Days)
- ACIU 109.7K
- FLC 37.8K
- Earning Date
- ACIU 08-05-2025
- FLC 01-01-0001
- Dividend Yield
- ACIU N/A
- FLC 6.64%
- EPS Growth
- ACIU N/A
- FLC N/A
- EPS
- ACIU N/A
- FLC N/A
- Revenue
- ACIU $36,362,036.00
- FLC N/A
- Revenue This Year
- ACIU N/A
- FLC N/A
- Revenue Next Year
- ACIU $1,022.98
- FLC N/A
- P/E Ratio
- ACIU N/A
- FLC N/A
- Revenue Growth
- ACIU 86.71
- FLC N/A
- 52 Week Low
- ACIU $1.43
- FLC $12.62
- 52 Week High
- ACIU $3.98
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- ACIU 44.83
- FLC 56.77
- Support Level
- ACIU $2.05
- FLC $17.11
- Resistance Level
- ACIU $2.19
- FLC $17.29
- Average True Range (ATR)
- ACIU 0.11
- FLC 0.09
- MACD
- ACIU -0.01
- FLC -0.01
- Stochastic Oscillator
- ACIU 4.55
- FLC 54.82
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.